Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02213081 · ClinicalTrials.gov registry record · Phase 4

Ulipristal for Endometriosis-related Pelvic Pain

A Phase 4 study, sponsored by Northwestern University.

Completed
Registry status
Phase 4
Development phase
1
Enrollment target

NCT02213081: Completed Phase 4 study, sponsored by Northwestern University.

NCT02213081 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02213081, a Phase 4 study, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 4
Development phase
1 participants
Enrollment target

Study Summary

The aim of this research is to assess the benefit of a medication (ulipristal) for alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.

Primary Outcome

Scores were collected daily and averaged together for each period

Interventions

  • DRUG Ulipristal

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2015-02
Est. Completion 2016-12
Phase Phase 4
Northwestern University

1,209 total trials

What the finished NCT02213081 record still lists

NCT02213081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 1 intervention - of which Ulipristal is the first listed.

NCT02213081 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02213081 about?

NCT02213081 is a clinical study titled "Ulipristal for Endometriosis-related Pelvic Pain". The aim of this research is to assess the benefit of a medication (ulipristal) for alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.

What is the current status of trial NCT02213081?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2015-02. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02213081?

The interventions under investigation include: Ulipristal (DRUG).

Who is sponsoring clinical trial NCT02213081?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02213081's enrollment target sits among peer trials

1 2000th of 2000 the lowest of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02213081, the US trial registry maintained by the National Library of Medicine. NCT02213081 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.